Basic information

2025/2008(INI) INI - Own-initiative procedure	Procedure completed
Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness **Subject** 3.50.04 Innovation 3.50.08 New technologies; biotechnology	

Key players

European Parliament

Committee responsible	Rapporteur	Appointed
ITRE Industry, Research and Energy	BENTELE Hildegard (EPP)	28/01/2025
	Shadow rapporteur HEINÄLUOMA Eero (S&D) DE LA PISA CARRIÓN Margarita (PfE) CICCIOLI Carlo (ECR) LØKKEGAARD Morten (Renew) BOESELAGER Damian (Greens/EFA) SMITH Anthony (The Left) SYPNIEWSKI Marcin (ESN)	

European Commission

Commission DG	Commissioner
Internal Market, Industry, Entrepreneurship and SMEs	-- --
Research and Innovation	-- --

Key events

Date	Event	Reference	Summary
23/01/2025	Committee referral announced in Parliament		
25/06/2025	Vote in committee		
01/07/2025	Committee report tabled for plenary	A10-0123/2025	
10/07/2025	Decision by Parliament	T10-0165/2025	Summary

10/07/2025	Results of vote in Parliament		

Technical information	
Procedure reference	2025/2008(INI)
Procedure type	INI - Own-initiative procedure
Procedure subtype	Initiative
Legal basis	Rules of Procedure EP 55
Stage reached in procedure	Procedure completed
Committee dossier	ITRE/10/01599

Documentation gateway

European Parliament

Document type	Committee	Reference	Date	Summary
Committee draft report		PE768.143	21/03/2025	
Amendments tabled in committee		PE772.136	15/04/2025	
Committee report tabled for plenary, single reading		A10-0123/2025	01/07/2025	
Text adopted by Parliament, single reading		T10-0165/2025	10/07/2025	Summary

European Commission

Document type	Reference	Date	Summary
Commission response to text adopted in plenary	SP(2026)06-25	25/06/2026	

Meetings with interest representatives published in line with the Rules of Procedure

Rapporteurs, Shadow Rapporteurs and Committee Chairs

Transparency

Name	Role	Committee	Date	Interest representatives
HEINÄLUOMA Eero	Shadow rapporteur	ITRE	19/05/2025	Future Affairs Consulting B.V.
BOESELAGER Damian	Shadow rapporteur	ITRE	15/05/2025	Re-Imagine Europa
LØKKEGAARD Morten	Shadow rapporteur	ITRE	13/05/2025	Confederation of Danish Industry European Biosolutions Coalition
HEINÄLUOMA Eero	Shadow rapporteur	ITRE	24/04/2025	Considerati for Pandemic Action Network
HEINÄLUOMA Eero	Shadow rapporteur	ITRE	10/04/2025	BASF SE
	Shadow			

HEINÄLUOMA Eero	rapporteur	ITRE	10/04/2025	Neste Oyj
HEINÄLUOMA Eero	Shadow rapporteur	ITRE	09/04/2025	UPM
HEINÄLUOMA Eero	Shadow rapporteur	ITRE	07/04/2025	International Biocontrol Manufacturers Association
HEINÄLUOMA Eero	Shadow rapporteur	ITRE	07/04/2025	Metsä Group
CICCIOLI Carlo	Shadow rapporteur	ITRE	07/04/2025	Pfizer Inc.
LØKKEGAARD Morten	Shadow rapporteur	ITRE	03/04/2025	European Federation of Pharmaceutical Industries and Associations
CICCIOLI Carlo	Shadow rapporteur	ITRE	03/04/2025	CEFIC
CICCIOLI Carlo	Shadow rapporteur	ITRE	03/04/2025	Novo Nordisk A/S
CICCIOLI Carlo	Shadow rapporteur	ITRE	01/04/2025	ECOLAB
CICCIOLI Carlo	Shadow rapporteur	ITRE	31/03/2025	USIPA
CICCIOLI Carlo	Shadow rapporteur	ITRE	31/03/2025	Dsm-Firmenich
HEINÄLUOMA Eero	Shadow rapporteur	ITRE	27/03/2025	Fresenius SE & Co.KGaA
HEINÄLUOMA Eero	Shadow rapporteur	ITRE	27/03/2025	EuropaBio
CICCIOLI Carlo	Shadow rapporteur	ITRE	26/03/2025	EWPA/EWPM
HEINÄLUOMA Eero	Shadow rapporteur	ITRE	26/03/2025	Bayer AG
LØKKEGAARD Morten	Shadow rapporteur	ITRE	26/03/2025	Bayer AG
LØKKEGAARD Morten	Shadow rapporteur	ITRE	25/03/2025	EuropaBio
LØKKEGAARD Morten	Shadow rapporteur	ITRE	21/03/2025	Visibuilt
HEINÄLUOMA Eero	Shadow rapporteur	ITRE	20/03/2025	Corbion
HEINÄLUOMA Eero	Shadow rapporteur	ITRE	20/03/2025	BIC
LØKKEGAARD Morten	Shadow rapporteur	ITRE	20/03/2025	TOPSOE A/S
HEINÄLUOMA Eero	Shadow rapporteur	ITRE	20/03/2025	CEFIC - European Chemical Industry Council
LØKKEGAARD Morten	Shadow rapporteur	ITRE	19/03/2025	Food Innovators Network
HEINÄLUOMA Eero	Shadow rapporteur	ITRE	11/03/2025	Cellular Agriculture Europe
LØKKEGAARD Morten	Shadow rapporteur	ITRE	06/03/2025	The Good Food Institute Europe (Belgium)

HEINÄLUOMA Eero	Shadow rapporteur	ITRE	04/03/2025	EFPIA
CICCIOLI Carlo	Shadow rapporteur	ITRE	03/03/2025	Assobiotec
CICCIOLI Carlo	Shadow rapporteur	ITRE	03/03/2025	EFPIA
BENTELE Hildegard	Rapporteur	ITRE	27/02/2025	International Biocontrol Manufacturers' Association
BENTELE Hildegard	Rapporteur	ITRE	27/02/2025	Association of Manufacturers and Formulators of Enzyme Products EuropaBio
BENTELE Hildegard	Rapporteur	ITRE	27/02/2025	Cellular Agriculture Europe
BENTELE Hildegard	Rapporteur	ITRE	27/02/2025	Verband der Chemischen Industrie e.V.
HEINÄLUOMA Eero	Shadow rapporteur	ITRE	18/02/2025	EWPM
HEINÄLUOMA Eero	Shadow rapporteur	ITRE	11/02/2025	EuropaBio
LØKKEGAARD Morten	Shadow rapporteur	ITRE	04/02/2025	Novo Nordisk A/S
HEINÄLUOMA Eero	Shadow rapporteur	ITRE	03/02/2025	Chemical Industry Federation of Finland (Kemianteollisuus ry)
LØKKEGAARD Morten	Shadow rapporteur	ITRE	28/01/2025	Finnish Forest Industries Federation (Metsäteollisuus ry)
BENTELE Hildegard	Rapporteur	ITRE	15/01/2025	Resilience Action Network International (rani), a fiscally sponsored project of Panorama Global Pour Demain Europe
LØKKEGAARD Morten	Shadow rapporteur	ITRE	19/12/2024	GIDE LOYRETTE NOUEL A.A.R.P.I.
HEINÄLUOMA Eero	Shadow rapporteur	ITRE	12/12/2024	Finnish Forest Industries Federation (Metsäteollisuus ry)

Other Members

Transparency		
Name	**Date**	**Interest representatives**
NEVADO DEL CAMPO Elena	06/06/2025	Resilience Action Network International (rani), a fiscally sponsored project of Panorama Global
NEVADO DEL CAMPO Elena	26/05/2025	Alliance for Regenerative Medicine
SMITH Anthony	10/04/2025	Grand Est-Europe
HANSEN Niels Flemming	17/01/2025	Association of Manufacturers and Formulators of Enzyme Products

Future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness

2025/2008(INI) - 10/07/2025 - Text adopted by Parliament, single reading

The European Parliament adopted by 494 votes to 83, with 71 abstentions, a resolution on the future of the EU biotechnology and biomanufacturing sector: leveraging research, boosting innovation and enhancing competitiveness.

Conditions for a comprehensive EU biotech act

Parliament pointed to the growth potential of the European biotechnology and biomanufacturing sector and the need for the EU to remain world-leading in this field.

Members called on the Commission, if it proposes **new EU-wide regulation** in the form of an EU Biotech Act, to address concrete gaps and shortcomings in the current legislation and its implementation, and to propose legislation that can be revised, simplified, streamlined and repealed and that reduces administrative burdens, paying particular attention to the specificities of the industry and respecting relevant safety and security standards. The legislation should be accompanied by an impact and cost assessment, and take into account the impact on SMEs and start-ups.

Parliament called on the Commission to:

- ensure that any future legislative initiative has a sufficiently broad scope to capture the width of the biotechnology and biomanufacturing industry and its full range of applications;

- present a report on the application of current legislation in the field of biotechnology which lists possible regulatory obstacles and gaps hindering the growth of industries employing these technologies and manufacturing processes;

- streamline, simplify and shorten the time required for authorisation procedures, particularly approval time frames, for biotechnology materials and products throughout their manufacturing- and life-cycles, and to facilitate the market uptake of bio-based solutions;

- consider the possibility of a simplified approvals procedure for biotechnological products already approved by trusted regulatory bodies in like-minded countries applying standards equivalent to those of the Union;

- consider simplifying labelling practices, such as the use of QR codes, and to ensure fair market conditions between biotechnology products and other products, for example in marketing and advertising.

The resolution underlined the strategic importance for the Union of having a **strong biotechnology ecosystem** to support research and development, the production of innovative medicines and patient access to them.

Need to promote the advantages and specificities of the biotechnology and biomanufacturing industries

Parliament called on the Commission to present an **updated bioeconomy strategy**, encouraging the development and production of sustainable and innovative bio-based materials, products and solutions with high added value, in order to contribute to the competitiveness and strategic autonomy of the Union.

The resolution highlighted the importance of adopting an open approach to different **biomass technologies** based on sound analysis, as well as the need to take into account the specificities of biogenic carbon. It highlighted the benefits of bioproducts and bioprocesses and their contribution to the Union's CO_2 emission reduction targets.

Members believe that, in order to accelerate the substitution of fossil-based feedstocks, market demand and uptake of **sustainable bio-based products** should be further encouraged within the EU. Bio-based raw materials, such as sustainable biomass, recycled waste and CO_2 captured from biogenic sources, could be used as alternative raw materials to manufacture various products.

Highlighting the potential of biotechnological applications when considering applications of biotechnology to food and feed, Parliament called on the Commission to identify pathways to market for **safe applications of biotechnology** in food products. **Biosafety** risks, including bioethical concerns, must also be addressed alongside innovation in biotechnology, ensuring responsible access to and use of synthetic biology tools, genetic editing technologies and biological materials.

Horizontal issues

Parliament underlined the importance for **supply chain security** of ensuring a sufficient, stable and competitive supply of feedstock, raw materials and essential components, such as sustainable biomass and enzymes for biotechnology and biomanufacturing companies. In an increasingly tense geopolitical context, biotechnology and biomanufacturing should be fully leveraged to strengthen the EU's strategic autonomy, enhance food security and reduce dependence on non-EU countries.

Members pointed to the need to (i) improve the transfer of knowledge and technology between academia and industry to ensure that EU-funded biotechnology research leads to commercial applications and industrial deployment; (ii) have a skilled and diverse European workforce in the biotechnology and biomanufacturing sector; and (iii) urgently complete the Capital Markets Union to attract institutional investors to the biotechnology industry.

Deploring the fact that European private investment in research, development and innovation lags behind that of other major economies, Parliament called for an EU-wide approach to **coordinating public investment in research and development** for biotechnology and biologics. The Commission is invited to integrate innovation in biotechnology and biomanufacturing innovation into the EU's digital and artificial intelligence strategies.